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ASBACKGROUND & AIMS: Incidence of and mortality from
pancreatic ductal adenocarcinoma (PDAC), the most common
form of pancreatic cancer, are almost equivalent, so better
treatments are needed. We studied gene expression proﬁles of
PDACs and the functions of genes with altered expression to
identify new therapeutic targets. METHODS: We performed
microarray analysis to analyze gene expression proﬁles of 195
PDAC and 41 non-tumor pancreatic tissue samples. We
undertook an extensive analysis of PDAC transcriptome by
superimposing interaction networks of proteins encoded by
aberrantly expressed genes over signaling pathways associated
with PDAC development to identify factors that might alter
regulation of these pathways during tumor progression. We
performed tissue microarray analysis to verify changes in
expression of candidate protein using an independent set of
152 samples (40 nontumor pancreatic tissues, 63 PDAC sec-
tions, and 49 chronic pancreatitis samples). We validated the
functional relevance of the candidate molecule using RNA
interference or pharmacologic inhibitors in pancreatic cancer
cell lines and analyses of xenograft tumors in mice. RESULTS:
In an analysis of 38,276 human genes and loci, we identi-
ﬁed 1676 genes that were signiﬁcantly up-regulated and
1166 genes that were signiﬁcantly down-regulated in PDAC
compared with nontumor pancreatic tissues. One gene that was
up-regulated and associated with multiple signaling pathways
that are dysregulated in PDAC was G protein subunit ai2, which
has not been previously associated with PDAC. G protein sub-
unit ai2 mediates the effects of dopamine receptor D2 (DRD2)
on cyclic adenosine monophosphate signaling; PDAC tissues
had a slight but signiﬁcant increase in DRD2 messenger RNA.
Levels of DRD2 protein were substantially increased in PDACs,
compared with non-tumor tissues, in tissue microarray ana-
lyses. RNA interference knockdown of DRD2 or inhibition with
pharmacologic antagonists (pimozide and haloperidol) reduced
proliferation of pancreatic cancer cells, induced endoplasmicFLA 5.4.0 DTD  YGAST60663_proof reticulum stress and apoptosis, and reduced cell migration.
RNA interference knockdown of DRD2 in pancreatic tumor cells
reduced growth of xenograft tumors in mice, and administra-
tion of the DRD2 inhibitor haloperidol to mice with orthotopic
xenograft tumors reduced ﬁnal tumor size and metastasis.
CONCLUSIONS: In gene expression proﬁle analysis of PDAC
samples, we found the DRD2 signaling pathway to be activated.
Inhibition of DRD2 in pancreatic cancer cells reduced prolif-
eration and migration, and slowed growth of xenograft tumors
in mice. DRD2 antagonists routinely used for management of
schizophrenia might be tested in patients with pancreatic
cancer.Keywords: TMA; Unfolded Protein Response; Drug Reposition-
ing; Pancreas.
he overall 5-year survival rate of all cancer patientsTstands at 63%, and only about 5% for pancreatic
cancer—a number that has remained largely unchanged for
the last 3 decades.1 Of the patients diagnosed with
pancreatic cancer, approximately 85% exhibit pancreatic24 October 2016  1:19 pm  ce





























































































PANCREASductal adenocarcinoma (PDAC); most of them die within 6
months after diagnosis. The poor prognosis is caused by a
lack of apparent symptoms early during the disease and
consequently its detection at only late stages. This goes
along with an aggressive tumor biology, in particular, very
early metastasis. Finally, effective options for chemotherapy
are lacking.2 The widely used chemotherapeutic agent
gemcitabine confers a median survival advantage of only 6
months,3 also because the vast majority of patients
develop resistance to therapy.4 Given this poor prospect,
there is an urgent need for effective treatment modalities.
To this end, we set out to investigate potential therapeutic
targets by dissecting gene expression proﬁles of tumors
and control samples. Candidate targets were validated with
respect to their suitability and analyzed functionally. Using
this approach, dopamine receptor D2 (DRD2) was found as
a novel, promising protein for the development of a
targeted therapy. We show that DRD2 has a central role in
proliferation and survival of pancreatic cancer cells. Phar-
macologic blockade of DRD2 activity with inhibitors,
including the Food and Drug Administration (FDA)
approved DRD2 antagonists pimozide and haloperidol,
suppressed the proliferation of pancreatic cancer cells,
while having a markedly attenuated effect on normal
ﬁbroblasts. Further functional assays demonstrated sub-
stantial effects on migration, cell cycle progression and
apoptosis as well, providing a broad therapeutic spectrum,































Detailed information describing methods used in each of
the following sections are provided in the Supplementary
Material.
Tissue RNA Proﬁling
The study was performed with tissue samples obtained
from patients admitted to the Department of General, Visceral
and Transplantation Surgery, University of Heidelberg and the
National Institute for Health Research, Liverpool. The study was
conducted in accordance with the Helsinki Declaration; written
informed consent was obtained from all patients; ethical
approval was obtained from the ethical committee of the Uni-
versity of Heidelberg (case number 301/2001). Total RNA from
individual samples was analyzed on the Sentrix Human-6v3
Whole Genome Expression BeadChips (Sentrix Human WG-6;
Illumina) as suggested by the manufacturer. Information
about clinical annotations of samples, isolation of RNA, and
microarray expression data analysis, as well as downstream
pathway and network analysis, are provided in Supplementary
Table 1 and Supplementary Material.
Cell Lines and Reagents
Five pancreatic cancer cell lines with various degree of
differentiation were obtained from the American Type Culture
Collection (Manassas, VA). The moderately differentiated BxPC-
3 cells, as well as the poorly differentiated cell lines
Panc-1 and MiaPaCa-2, originated from primary tumor. TheFLA 5.4.0 DTD  YGAST60663_proof well-differentiated cell lines Capan-1 and CFPAC-1 were
isolated from liver metastases of pancreas adenocarci-
noma. Normal human dermal ﬁbroblasts were obtained
from PromoCell (Heidelberg, Germany). Pimozide, L-741,626,
haloperidol, thapsigargin, SQ22536, and H-89 were purchased
from Sigma-Aldrich (Munich, Germany).
Plasmids and Viral Transduction
All lentiviral short hairpin RNA (shRNA) vectors were
obtained from the Mission TRC genome-wide shRNA collection
of Sigma-Aldrich. Additional information about the shRNA
vectors can be found at http://www.broad.mit.edu/genome_
bio/trc/rnai.html using the TRCN number. The follow-
ing lentiviral shRNA vectors targeting DRD2 or ATF4
were used:TRCN0000011342 (shDRD2#1), TRCN0000011343
(shDRD2#2), TRCN0000013573 (shATF4#1), and
TRCN0000013575 (shATF4#2). Vector pLKO.1 was used as




For mice xenograft tissue samples and cultured cells, the
miRNeasy kit (Qiagen, Valencia, CA) was used to extract total
RNA. Reverse transcription was done using the Maxima First
Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientiﬁc
Rockford, Logan, UT). Real-time polymerase chain reaction was
run using the ViiA 7 Real-Time PCR System (Applied Bio-
systems, Darmstadt, Germany) and the FastStart Universal
SYBR Green Master Mix (Roche Diagnostics, Mannheim,
Germany) according to the manufacturers’ speciﬁcations.
Relative messenger RNA levels of DRD2 were normalized to
the expression of the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase. Quantiﬁcation values were calcu-
lated according to a standard curve method created from a
dilution series. Polymerase chain reactions were performed in
triplicate.
Western Blot Analysis
Western blot analysis was performed as described previ-
ously.5 Detailed procedure and antibodies are described in the
Supplementary Material.
Colony-Formation Assay
Single-cell suspensions of the indicated parental or trans-
duced pancreatic cancer cell lines were plated in 6-well plates
(2–4  104 cells/well), and were cultured for 12–15 days while
growth medium was refreshed every 4 days. Cells were
then washed with phosphate-buffered saline, ﬁxed with
paraformaldehyde, stained with crystal violet (0.1% w/v;
Sigma-Aldrich) and photographed. Assays were performed
independently at least 3 times.
Measurement of the Free Ca2þ
Concentration in Cytosol
Intracellular Ca2þ levels were measured using the Fluo-4
NW Calcium Assay Kit (Invitrogen, Karlsruhe, Germany)




Table 1.Characteristics of the Patients Whose Tumors Were
Analyzed by Gene Expression Proﬁling



















Age, y, median (range) 68 (4388)
NA, XX. Q12









































































































































Cancer cells were plated into the wells of 12-well plates
(NUNC, Roskilde, Denmark) and allowed to grow for 24 hours.
Drug treatment was performed for 48 hours with different
concentrations. Cells were harvested by trypsinization and
washed with cold phosphate-buffered saline. Cold Nicoletti
buffer was used for staining and the DNA content of single
nuclei was analyzed by ﬂow cytometry on a FACSCANTO II
analyzer (BD Biosciences, Heidelberg, Germany) with collection
of at least 10,000 events for each sample and in 3 independent
experimental repetitions.
Cell Viability
Sulforhodamine B sodium salt (Sigma-Aldrich) assay was
used to assess cell viability.
Caspase 3/7 Activity
The cell apoptosis caused by DRD2 antagonists was deter-
mined using the Caspase-Glo 3/7 Assay kit (Promega, Madison,
WI) according to the manufacturer’s instructions.
In Vivo Experiments
Severe combined immunodeﬁcient beige mice were bred
in-house. One million Panc-1 cell transduced with shDRD2#1,
shDRD2#2, or pLKO were suspended in 150 mL phosphate-
buffered saline and mixed with 150 mL Matrigel (BD Bio-
sciences, San Jose, CA) before the respective suspension was
injected subcutaneously into the left and right ﬂank of a mouse.
For each test cell line, 3 mice were injected with cells in both
ﬂanks. Tumor size was determined twice a week using a caliper
to measure the volume of the tumor according to the formula:
volume (V) ¼ length (L)  depth (D)  width (W). After
reaching the appropriate volume, primary tumors were resec-
ted. In case of pLKO, this happened on day 51 after injection;
for shDRD2#1 and shDRD2#2 the tumor was removed after 65
days. Tumors were embedded in parafﬁn after zinc ﬁxation for
immunohistochemistry and H&E staining, or stored at 80C
for RNA extraction.
Two million MIAPaCa-2 cells resuspended in 10 UL Matrigel
(BD Biosciences, San Jose, CA) were orthotopically implanted
into the tail of the pancreas of 6-week-old Nod scid gamma
animals (Jackson Labs, Bar Harbor, ME) (day 1). When tumors
were palpable (day 27), mice were randomized into 2 groups
(n ¼ 7 in control group and n ¼ 9 in haloperidol group) and
injected intraperitoneally with either haloperidol (10 mg/kg)
or solvent (dimethylsulfoxide [DMSO] control group) for 12
days. The experiment was terminated when control mice
appeared moribund. Weight of the animal and ﬁnal tumor
weight and volume were measured. The studies were approved
by the Animal Care Committee of McGill University Faculty of
Medicine.
Statistical Analysis
GraphPad Software 6 for Windows (GraphPad, San Diego,
CA), SigmaPlot 12.5 (Systat Software, San Jose, CA) and
Microsoft Excel 2010 (Redmond, WA) were used for statistical
analysis and graph creation. Data are presented as mean
SE from 3–8 independent experiments, depending on theFLA 5.4.0 DTD  YGAST60663_proof assay. An analysis of difference between the mean of 2 data
sets was carried out using the nonparametric Mann-
Whitney U test. P values <.05 were considered as statistically
signiﬁcant.Results
Gene Expression Proﬁling Identiﬁes Pancreatic
Ductal AdenocarcinomaAssociated Pathways
We examined the expression proﬁles of 38,276 human
genes and loci across pancreatic tissue samples from 195
PDAC patients and 41 healthy control subjects (Table 1 and
Supplementary Table 1; the complete data set is accessible
at the public ArrayExpress database [E-MTAB-1791]). This
analysis revealed widespread deregulation of gene expres-
sion in PDAC, including 1676 and 1166 genes that were
substantially up- or down-regulated in PDAC, respectively
(false discovery rate <0.01, Supplementary Table 2).
Interestingly, we found that many up-regulated genes were
associated with several cancer-related pathways according
to the Kyoto Encyclopedia of Genes and Genomes6 data sets,
with the most signiﬁcant association corresponding to
“pathways in cancer” (P < 5  109; Figure 1A and
Supplementary Table 3). Many of the genes associated with
“pathways in cancer” were also linked to other PDAC-
enriched processes (Figure 1B), suggesting a central role
for these “multipathway” genes as potential functional hubs
contributing to PDAC. This was further supported by several
previous studies Qthat reported a connection between these
genes and pancreatic cancer (Figure 1B and Supplementary
Table 4), highlighting the notion that many of these multi-
pathway genes are reproducibly linked to PDAC.
One of the PDAC-related multipathway genes was
















Figure 1.Gene expression analysis. (A) Pathways or functions that are signiﬁcantly up- or down-regulated in the PDAC
transcriptome are shown in red and blue, respectively (false discovery rate [FDR] <0.025). The number of signiﬁcantly
de-regulated genes of each pathway (FDR <0.01, fold-change >1.5) is shown on the right. (B) Top 15 multipathway genes of
the “pathways in cancer” annotation. For each gene, the total number of up-regulated PDAC pathways is indicated. Genes that
were previously reported to have association with pancreatic cancer, or to have a pancreatic cancer-associated homolog, are
marked (see Supplementary Table 4 for a list of publications related to each gene). (C) GNAI2, as the top multipathway
candidate for pancreatic cancer that has not been previously implicated, directly interacts with several other PDAC
de-regulated proteins, the majority of which are also up-regulated. Most interactions are with other components of the GPCR
signaling pathway. Among the up-regulated interacting partners in this signaling pathway, DRD2 is an aberration hub, with a
signiﬁcant proportion of its ﬁrst and second-degree neighbors being up-regulated in PDAC samples. Other aberration hubs are
also identiﬁed by their names. (D) Immunohistochemical analysis of DRD2 protein levels in PDAC samples on tissue micro-
arrays. Representative examples of DRD2 expression in duct cells of normal pancreas, CP and PDAC are shown. Normal
ductal cells were almost DRD2-negative or showed a mild positivity in pancreatic ducts. CP lesions and PDACs represented
moderate/strong and strong DRD2 expression, respectively. Sizing bar indicates 100 mm. (E) The staining intensity was
categorized into 4 groups: <1 ¼ no or poor staining (negative); 1 ¼ weak staining; 2 ¼ moderate staining; and 3 ¼ strong
staining. The distribution of DRD2 expression in the clinical tissue samples revealed its high expression in PDAC (P < 1013)
and CP (P < 106) as compared with normal tissues. P values were calculated by Student t test.



























































































































PANCREASpolypeptide 2 (GNAI2). Surprisingly, we did not ﬁnd any
previous report about a connection of GNAI2 and pancreatic
cancer, despite its clear up-regulation in PDAC (P< 3 1012,
fold-change >2) and its association with 9 PDAC-related
pathways. GNAI2 is an a subunit of the guanine nucleotide-
binding proteins (G proteins) and primarily functions in
G-protein coupled receptor (GPCR) signaling by regulation of
adenylate cyclase.7 In addition, we observed that GNAI2
interacts with several genes that were up-regulated in PDAC,
particularly other proteins of the GPCR and cyclic
adenosine monophosphate (cAMP pathways) (Figure 1C),FLA 5.4.0 DTD  YGAST60663_proof further supporting its role as a functional signaling hub in
PDAC.GNAI2 Interacting Partner Dopamine Receptor
D2 Is Up-Regulated in Pancreatic Ductal
Adenocarcinoma
GNAI2 couples cell surface receptors to intracellular
pathways, primarily to cAMP signaling.8 In order to identify
cell surface receptors that may take advantage of GNAI2



























































































555systematically looked for “aberration hubs” among the
interacting partners of GNAI2 that were up-regulated in
PDAC. An aberration hub is deﬁned as a protein that exhibits
an unexpectedly large number of physical or functional
interactions with “aberrant” proteins; in this case proteins
that are signiﬁcantly up-regulated in PDAC (see Materials
and Methods). Aberration hubs often highlight proteins that
are central in disease modules.9 We identiﬁed 6 signiﬁcant
aberration hubs among the interacting partners of GNAI2
that are involved in GPCR signaling (false discovery rate
<0.01, Figure 1C). One of them is DRD2, which uses GNAI2
to regulate the cAMP-signaling pathway, the deregulation of
which is intrinsic to pancreatic cancer.10 However, in PDAC
samples, the microarray analysis only identiﬁed a slight,
although very signiﬁcant, increase in DRD2 messenger RNAFigure 2. Silencing of DRD2 inhibits cancer cell growth in vitro
Panc-1 cells infected with the lentiviral vector pLKO as a contr
geting DRD2 (shDRD2#1 and #2). The cells were ﬁxed, stained,
was assessed by quantitative reverse transcription polymerase
was monitored by measuring tumor volume in mice implanted
shDRD2 (3 mice per group, each implanted with cells in both ﬂan
implanted with DRD2-deﬁcient cells (P ¼ .002). (C) Representa
from mice. H&E staining did not show any pathologic differenc
exception of cell ballooning in some areas of a tumor generat
marker of cell proliferation conﬁrmed decreased proliferation in
conﬁrmed the efﬁcacy of knockdown. Sizing bar indicates 50 mm
described in (C) for all tumors (n ¼ 18). Data are presented as m
compared with the corresponding results from pLKO-infected c
FLA 5.4.0 DTD  YGAST60663_proof levels (1.08-fold; P < .0002). This initially suggested that
low levels of DRD2 could act as a bottleneck in this pathway,
therefore, limiting the effect of GNAI2 up-regulation. How-
ever, tissue microarray analysis of DRD2 across 40
normal pancreatic tissues, 63 PDAC sections, and 49 sam-
ples of chronic pancreatitis (CP), an inﬂammation of
the pancreas associated with high risk of PDAC11
(Supplementary Table 5), revealed that DRD2 protein
levels were signiﬁcantly increased in PDAC and CP
compared with normal samples (>3-fold), with the highest
level detected in PDAC (>4-fold, P < 1013, Figure 1D and
E). These results mirrored up-regulation of GNAI2 in PDAC
and suggested that DRD2 up-regulation, most likely due
to a post-transcriptional aberration, may contribute to
malignancy.and in vivo. (A) Colony-formation assay with MiaPaCa-2 and
ol or constructs expressing 1 of 2 independent shRNAs tar-
and photographed after 12 days. The efﬁcacy of knockdown
chain reaction (Supplementary Figure 1A). (B) Tumor growth
with Panc-1 cells expressing the negative control (pLKO) or
ks). There was a signiﬁcant decrease in tumor growth in mice
tive ﬁgures of histologic examination of the tumors procured
e in DRD2-deﬁcient tumors compared with controls, with the
ed from cells infected with shDRD2#2. Staining for Ki-67, a
DRD2-deﬁcient cells. Analysis with an antibody against DRD2
. (D) Bar plots summarizing the immunohistochemistry results
ean ± SE throughout the ﬁgure. *P < .05 and **P < .01 when
ells (Mann-Whitney U test).






















































































































































PANCREASSilencing of Dopamine Receptor D2 Inhibits
Cancer Cell Growth in Vitro and in Vivo
To determine whether DRD2 contributes to tumor cell
growth and survival, we suppressed DRD2 expression in the
pancreatic cancer cell lines Panc-1 and MiaPaCa-2 through
lentiviral delivery of expression vectors of shRNAs targeting
DRD2. Knockdown of DRD2 expression by 2 independent
shRNA constructs impaired proliferation of both cell lines as
measured by a long-term colony-formation assay (Figure 2A
and Supplementary Figure 1A).FLA 5.4.0 DTD  YGAST60663_proof For conﬁrmation in vivo, we subcutaneously injected
1  106 Panc-1 cells expressing either of the 2 shRNAs
targeting DRD2 or the pLKO control into severe combined
immunodeﬁcient beige mice, with 2 replicates, and moni-
tored tumor size over time. Mice implanted with pLKO-
expressing cells developed tumors much earlier (21.7
± 1.6 days) than those engrafted with DRD2-deﬁcient cells
(33.3 ± 1.2 days with shDRD2#1 or 27.2 ± 1.5 days with
shDRD2#2). Mice engrafted with DRD2-deﬁcient cells

































































































































































ASwith the control group (P<.002, Figure 2B), while there was
no signiﬁcant difference in body weight between control
and test groups (Supplementary Figure 1B). Immunohisto-
chemical analysis of the tumors conﬁrmed the reduced
levels of DRD2 in tissues isolated from animals treated with
DRD2-deﬁcient cells compared with the controls (Figure 2C
and D), in line with lower DRD2 messenger RNA levels in
tumors developed from DRD2-deﬁcient cells as assayed
by quantitative reverse transcription polymerase chain
reaction (Supplementary Figure 1C). Concomitant to the
reduction in DRD2, protein Ki-67—a marker of cell pro-
liferation12—was markedly reduced (Figure 2C and D).
These results demonstrated that DRD2 has a key role in
proliferation and survival of tumor cells.
Pharmacologic Blockade of Dopamine Receptor
D2 Impairs Cancer Cell Growth
We examined the effect of pharmacologic inhibition of
DRD2 on cancer cell proliferation. Different concentrations
of the DRD2 antagonist pimozide, an FDA-approved DRD2
inhibitor used for treatment of schizophrenia,13 were tested
on 5 established pancreatic cancer cell lines—Panc-1,
CFPAC-1, Capan-1, MiaPaCa-2, and BxPC-3. Treatment with
pimozide resulted in a dose-dependent inhibitory effect on
cell growth in all examined cell lines. Notably, the pimozide
effect was stronger in MiaPaCa-2 and BxPC-3 cells, which
showed higher expression levels of DRD2 among the cell
lines, and weaker on a primary normal ﬁbroblast cell line
used as a control (Figure 3A). We repeated the assay with
another DRD2 inhibitor, L-741,626 (L-741).14 L-741 treat-
ment had virtually the same effect (Supplementary
Figure 2A). Taken together, our results demonstrated that
pharmacologic blockade of DRD2 activity inhibits prolifer-
ation of pancreatic cancer cells.
Induction of Endoplasmic Reticulum Stress in
Response to Dopamine Receptor D2 Blockade
Deﬁciency of DRD2 leads to endoplasmic reticulum (ER)
stress,15 the severe form of which has anti-proliferative and
pro-apoptotic effects in cancer cells.16 We examined the=
Figure 3. Pharmacologic blockade of DRD2 reduces cell viabil
PaCa-2, BxPC-3, and ﬁbroblast cells were seeded for 24 hou
pimozide for 72 hours. Cell viability was determined using th
independent experiments. Middle: DRD2 levels in the cell lines
treatment with increasing doses of pimozide on colony-forming a
ER stress in MiaPaCa-2 (top) and Panc-1 (bottom) cells. Cells w
of pimozide for 2 hours. Protein was extracted and equal amou
dicator antibodies PERK and p-PERK. (C) Effect of pimozide an
(top) and Panc-1 (bottom) cells. Cells were treated with the F
recorded for 10 seconds. Then, Pimozide, L741 or DMSO was
mean of 3 independent assays was normalized to their baselines
MiaPaCa-2 (top) and Panc-1 (bottom) cells. Cells were seeded
hours. Total protein was extracted and equal amounts of cell lysa
PKA substrate antibody. (E) Inhibition of PKA by SQ22536 and H
by a reduced release of Ca2þ from the ER to the cytoplasm. Pan
dye; baseline values were recorded for 10 seconds after pretrea
pimozide or DMSO. Fluorescence was measured for 100 secon
their baseline values.
FLA 5.4.0 DTD  YGAST60663_proof possible effect of DRD2 blockade on induction of ER stress
by evaluating the level of phosphorylated PERK (Thr 981).
Pimozide increased phosphorylation of PERK in a dose-
dependent manner in both Panc-1 and MiaPaCa-2 cells, as
determined by immunoblotting (Figure 3B). Similar results
were obtained by treating cells with L-741 (Supplementary
Figure 2B). As ER stress is coupled to the release of Ca2þ
from the ER into the cytosol,17 we examined whether DRD2
inhibition would affect the cytosolic abundance of Ca2þ.
Indeed, treatment with both pimozide and L-741 increased
the concentration of cytosolic Ca2þ within seconds in Panc-1
and MiaPaCa-2 (Figure 3C), showing that DRD2 blockade
induces ER stress in PDAC cells.
Cyclic Adenosine Monophosphate and Protein
Kinase A Mediates the Effects of Dopamine
Receptor D2 Inhibition on Endoplasmic
Reticulum Stress
It has been shown that cAMP and protein kinase A (PKA)
regulate Ca2þ levels in the cytosol and are involved in ER
stress.18,19 It has also been reported that DRD2 modulates
intracellular cAMP formation.20 Accordingly, we examined
whether induction of ER stress by DRD2 blockade would be
mediated by cAMP and PKA. To this end, the activity of PKA,
which is dependent on the presence of cAMP, was measu-
red through Western blot analysis using a phospho-PKA
substrate antibody in Panc-1 and MiaPaCa-2 cells
following treatment with pimozide. Activation of PKA was
detected upon incubation with 1 mM pimozide. The effect
grew stronger with the administration of higher drug con-
centrations (Figure 3D), indicating that cAMP/PKA is acti-
vated in a dose-dependent manner upon inhibition of DRD2.
In order to examine whether the ER stress induced by
DRD2 inhibition is inﬂuenced by modulation of cAMP or
PKA, Panc-1 cells were pretreated with SQ22536, a speciﬁc
cAMP inhibitor, to down-regulate cAMP and PKA activation;
alternatively, the drug H-8921 was used to block PKA.
Strikingly, the pimozide-induced release of Ca2þ from the
ER to cytoplasm was completely blocked or substan-
tially reduced by a pretreatment with SQ22536 or H-89,ity in PDAC cells. (A) Left: Panc-1, CFPAC-1, Capan-1, Mia-
rs and subsequently exposed to various concentrations of
e sulforhodamine B assay. Values are the mean ± SD of 6
assayed by Western blot. Right: Effect of long-term (15 days)
bility of Panc-1. (B) The effect of pimozide on the activation of
ere seeded for 24 hours and then treated with different doses
nts of cell lysates were analyzed by WB using ER stress in-
d L741 on Ca2þ release from ER to cytoplasm in MiaPaCa-2
luo-4 dye 24 hours after seeding and baseline values were
added. Fluorescence was measured for 90 seconds and the
. (D) Dose dependent induction of PKA activity by pimozide in
for 24 hours and subsequently treated with pimozide for 2
tes were analyzed by Western blot analysis using a phospho-
-89 rescued the ER stress induced by pimozide, documented
c-1 cells were seeded for 24 hours and treated with the Fluo-4
tment with SQ 22536 and H-89. Then, cells were treated with
ds and the mean of 3 independent assays were normalized to
















































































































PANCREASrespectively (Figure 3E). The stronger reduction of Ca2þ
levels by SQ22536 may be explained by the ﬁnding that
cAMP affects all calcium transport system receptors in the
ER, whether they are PKA-dependent or not.18 Together, our
ﬁndings showed that DRD2 antagonists increase cytosolic
levels of Ca2þ in a rapid and effective manner; the
level of cAMP, which acts downstream of DRD2,22,23 is
increased after the blockade of DRD2; and Ca2þ levels areFLA 5.4.0 DTD  YGAST60663_proof positively regulated by cAMP mainly and to a lesser extent
by PKA.
Dopamine Receptor D2 Blockade Impairs Cell
Cycle Progression and Induces Apoptosis
Previous studies have shown that ER stress can affect
the cell cycle at the G1/S transition via regulating cyclin






































































































































1040inhibition on cell cycle progression. Panc-1 and MiaPaCa-2
cells were treated with different concentrations of Pimo-
zide for 48 hours and their distribution in the cell cycle
states was analyzed using ﬂuorescence-activated cell sort-
ing. Pimozide-induced cell cycle arrest at the G1 phase in
a dose-dependent manner (Figure 4A). In addition, the
increase in the fraction of cells in sub-G1 in the
ﬂuorescence-activated cell sorting analysis indicated a
higher number of apoptotic cells. To verify this, activation of
caspase 3/7 was examined 24 hours post-treatment with
pimozide. Caspase 3/7 activity grew with increasing pimo-
zide concentrations (Figure 4A), conﬁrming that inhibition
of DRD2 induces apoptosis in PDAC cells.
We further validated the induction of cell cycle arrest at
a molecular level by measuring the abundance of cell cycle
checkpoint proteins. Consistent with the ﬂuorescence-
activated cell sorting data, Western blot analysis showed a
decrease in the cyclin D1, p-Rb, and cyclin E1 levels, and an
increase in the levels of p21 and p27 in a dose-dependent





























ASDopamine Receptor D2 Inhibition Activates
Unfolded Protein Response in Pancreatic
Cancer Cells
As reported here, the blockade of DRD2 led to phos-
phorylation and thus activation of PERK, which is a marker
of unfolded protein response (UPR). Recent studies have
shown that a strong induction of UPR as indicated by PERK
activation can lead to UPR-induced apoptosis through
phosphorylation of downstream molecule eIF2a and selec-
tive induction of ATF4, which in turn increases the expres-
sion of CHOP.26 Therefore, we examined the activity and
expression levels of proteins involved in the PERK arm of
UPR after treatment of cells with pimozide (Figure 4C).
Phosphorylation of eIF2a as well as the expression levels of
ATF4 and CHOP increased upon pimozide treatment in a
dose-dependent manner, in line with the increase in acti-
vated PERK (Figure 3B). We further investigated the
induction of UPR in DRD2-deﬁcient cells in vivo. In severe
combined immunodeﬁcient beige mice, the abundance of=
Figure 4. Pimozide induces apoptosis and cell cycle arrest at G
were seeded for 24 hours and treated with increasing concentra
stained with Nicoletti buffer, and cell cycle distribution was ana
cells increased with increasing pimozide concentrations in both
and MiaPaCa-2 cells (P < 7  104 and < 4  105 for sub-G1
with higher pimozide concentrations in both Panc-1 and MiaPa
obtained by regression slope t test). Right: Dose-dependent a
pimozide. Panc-1 and MiaPaCa-2 were exposed to pimozide a
was measured. (B) The effect of pimozide on cell cycle checkp
treated with pimozide. Equal amounts of cell lysate were analyz
Pimozide activates the PERK signaling cascade of UPR. Phosp
were assayed by Western blot analysis after 2-hour and 24-ho
Silencing of DRD2 induces the PERK signaling cascade of UPR
increased levels of CHOP and P-elF2a as assayed by immun
analysis are shown. Inhibition of ER stress-UPR activation th
proliferative (E) and apoptosis-inducing (F) effects of pimozid
thapsigargin, serves as a positive control. **P < .01 when compa
(Mann-Whitney U test).
FLA 5.4.0 DTD  YGAST60663_proof phosphorylated eIF2a (p-eIF2a) and CHOP was assessed in
tumors that developed after implantation of Panc-1 cells
infected with shDRD2 constructs or the pLKO control.
Immunohistochemical analysis on tumor samples demon-
strated the elevated levels of p-eIF2a and CHOP in tumors
developed from DRD2-deﬁcient cells as compared with the
control tumors (Figure 4D). These ﬁndings provide evidence
that inhibition of DRD2 triggers UPR. To investigate the
extent to which activation of ER-UPR signaling mediates
growth inhibitory function of DRD2 blockade, we generated
ATF4-deﬁcient sublines of Panc-1 and MiaPaca-2 cells
through stable knock-down using 2 speciﬁc ATF4-shRNAs
(Supplementary Figure 3A and B), and examined effects of
DRD2 inhibition in these models. Likewise, we tested effects
of the ER stress inducer, thapsigargin,27 on cell viability and
apoptosis in these cells. Reduction of cell viability and
induction of apoptosis after treatment with pimozide or
thapsigargin were signiﬁcantly declined in ATF4-deﬁcient
cells compared with control (pLKO) (Figure 4E and F).
Similar results were obtained after treatment of these cells
with L-741 (Supplementary Figure 3CF). These results
show that the UPR pathway is an important mediator of
growth inhibitory effects of DRD2 blockade.Blockade of Dopamine Receptor D2 Inhibits
Cancer Cell Migration
Our previous results showed that DRD2 regulates the
cAMP level, which is known to modulate cell adhesion and
motility in pancreatic cancer cells.10 Consequently, we
studied whether DRD2 inhibition has an effect on cancer cell
migration by assessing the motility of the highly invasive
Panc-1 cells in a wound healing assay in the presence of the
DRD2 antagonists pimozide and L-741. Both antagonists
reduced migration of Panc-1 cells in a dose-dependent
manner using concentrations that did not inhibit cell
growth (Figure 5A and Supplementary Figure 4A and B).
Consistent with this result, we observed a gradual rise in the
expression of E-cadherin protein and a simultaneous
decrease in vimentin levels (Figure 5B). To exclude the
possibility that the effect of DRD2 inhibition on cell1 phase in PDAC cells. (A) Left: Panc-1 and MiaPaCa-2 cells
tions of pimozide or DMSO for 48 hours. Cells were ﬁxed and
lyzed by ﬂuorescence-activated cell sorting. Sub-G1 and G1
Panc-1 (P < .003 and <.001 for sub-G1 and G1, respectively)
and G1, respectively). Conversely, S-phase cells decreased
Ca-2 (P < .003 and <3  105, respectively; all P values are
ctivation of caspase 3/7 in PDAC cells after treatment with
nd DMSO as control for 24 hours. Then, caspase 3/7 activity
oint proteins. Total protein was extracted from Panc-1 cells
ed by Western blot using antibodies against each protein. (C)
horylation of eIF2a and expression levels of ATF4 and CHOP
ur treatment with pimozide in Panc-1 cells, respectively. (D)
in tumors of xenograft mice. Left: Knockdown of DRD2 led to
ohistochemistry (IHC). Right: Representative images of IHC
rough ATF4 knockdown rescues, at least in part, the anti-
e on Panc-1 and MiaPaca-2 cells. The ER stress inducer,
red with the corresponding results at 0 mM or pLKO condition








































Figure 5. Inhibitory effect of DRD2 blockade on migration of pancreatic cancer cells. (A) A wound was made in the conﬂuent
monolayer culture of Panc-1 cells. Cells were then exposed to increasing concentration of pimozide or DMSO for 10 hours
until the gap closed in the DMSO control. The size of the wound gap at 10 hours was compared with the size at time zero for
each drug concentration. (B) Consistent with inhibition of cell migration, pimozide treatment increased E-cadherin and
decreased vimentin protein levels in a dose-dependent manner in Panc-1 cells. (C) The dose-dependent inhibitory effects of
pimozide and L741 on the migration of MiaPaCa-2 cells. Cells were plated on Transwells (Boyden chamber) and migrated cells
were counted and normalized to controls after exposure to different doses of pimozide or L-741 for 4 hours. (D) Inhibition of
cAMP/PKA rescued the inhibitory effect of DRD2 blockade on the migration of Panc-1 cells. Cells were plated on Transwells
and exposed to L-741 (left) or pimozide (right) for 4 hours in the presence or absence of H89 or SQ22536, and cell migration
assayed as described in (C). Values are the mean of 4 replicate experiments. *P < .05 and **P < .01 when compared with the
corresponding results at 0 mM (Mann-Whitney U test).


















































































































PANCREASmigration was speciﬁc for the 2-dimensional wound healing
assay, we examined the migration of Panc-1 cells by the
quantitative 3-dimensional Boyden chamber assay in the
presence of pimozide, which conﬁrmed that the treatment
suppresses cell migration (Supplementary Figure 4C).
Furthermore, we validated the inhibitory effect of pimozide
and L-741 on pancreatic cancer cell migration by testing
another cell line (MiaPaCa-2) (Figure 5C). In order to verify
the involvement of the cAMP/PKA pathway in the observed
inhibitory effect of DRD2 blockade, we analyzed cell
migration while perturbing this pathway. The reduction in
cell migration upon treatment with pimozide or L-741 was
rescued by the addition of H89 or SQ22536, which both
reduce PKA activation and cAMP levels (Figure 5D, and
Supplementary Figure 4D). Taken together, these results
demonstrated that the DRD2 blockade suppresses pancre-









1199Blockade of Dopamine Receptor D2 Reduces
Tumor Growth and Metastasis in Vivo
We replicated anti-cancer effects of DRD2 inhibition using
another FDA-approved DRD2 antagonist haloperidol.28
Haloperidol treatment showed the same effects as
those observed with pimozide and L-741 treatments
(Figure 6AE). Interestingly, however, haloperidol displayedFLA 5.4.0 DTD  YGAST60663_proof the lowest toxicity on normal ﬁbroblast cells among DRD2
inhibitors examined in our study. Therefore, we set out to
verify the anti-cancer effects of haloperidol in orthotopic
models of pancreatic cancer, which we generated by
implanting MiaPaCa-2 cells into the tail of the pancreas of
Nod scid gamma mice. After tumor development, mice were
randomized into 2 groups and treated with haloperidol
(n ¼ 9) or control solvent (n ¼ 7). Haloperidol treatment
(10 mg/kg selected based on results reported for glioblas-
toma treatment29) reduced tumor volume, weight, and met-
astatic dissemination signiﬁcantly (P < .001), while showing
no signiﬁcant effect on animal weight (Figure 6F).Discussion
Investigating novel targeted therapeutic opportunities
for PDAC, we applied a combination of pathway- and
network-based approaches to PDAC transcriptome proﬁles.
Speciﬁcally, we leveraged on identifying aberration hubs by
overlaying PDAC-associated gene expression patterns on the
human protein interaction network in order to highlight
factors with potential driver activities among the plethora of
deregulated genes. This led to the identiﬁcation of DRD2,
which we validated as a novel promising therapeutic target.
Our ﬁndings revealed a high expression of DRD2 in PDAC,
and conﬁrmed the efﬁcacy of its blockade to suppress can-
















Figure 6. Anti-cancer effects of haloperidol. (A) Does-dependent anti-proliferative effects of haloperidol on pancreatic cancer
cells assayed by sulforhodamine B assay 72 hours post-treatment. (B) Induction of apoptosis by haloperidol as measured by
assaying caspase 3/7 activation 24 hours after treatment. Inhibition of ER stress-UPR activation through ATF4 knockdown
rescues, at least in part, the anti-proliferative (C) and apoptosis-inducing (D) effects of haloperidol on Panc-1 and MiaPaCa-2
cells. (E) Inhibition of cAMP/PKA rescued the inhibitory effect of haloperidol (Hal) on the migration of Panc-1 (left) and
MiaPaCa-2 (right) cells. (F) Treatment with haloperidol reduces tumor volume and metastasis burden in vivo. MiaPaCa-2 cells
(2  106) were orthotopically injected into the tail of the pancreas of NSG mice. Twenty-seven days post-surgery, mice were
randomized into 2 groups and treated with either haloperidol (10 mg/kg, intraperitoneal) or vehicle for 12 days. The experiment
was terminated when control animals became moribund. Animal weight, tumor weight, and tumor volume were measured at
time of sacriﬁce. Upper panel: Tumor weight (left) and volume (middle) were signiﬁcantly reduced in mice treated with halo-
peridol compared with the control group, while there was no signiﬁcant change in body weight (right) between groups. Bottom
panel: Representative images show tumors in mice. White and yellow outlines show primary and metastatic tumors,
respectively. Treatment with haloperidol reduced the metastasis dissemination. **P < .01 when compared with the corre-
sponding results at 0 mM in (B), pLKO at 30 mM in (D) or haloperidol at 20 mM in (E) (Mann-Whitney U test).







































































































































ASWe found that DRD2 blockade has an anti-proliferative
effect in pancreatic cancers, while activating ER stress, in
line with previous studies reporting that the deﬁciency of
DRD2 induces ER stress.15 The accelerated proliferation of
cancer cells in solid tumors often leads to nutrient depri-
vation in their microenvironment and results in protein
misfolding, which eventually triggers activation of ER
stress.16 Whereas moderate ER stress supports cell survival
in nutrient-deprived conditions, excessive ER stress leads to
cell cycle arrest and apoptosis,30,31 and has emerged as an
attractive anti-cancer therapeutic avenue.32,33 As such,
inhibiting DRD2 provides a targeted approach to activate ER
stress in cancer cells.FLA 5.4.0 DTD  YGAST60663_proof Importantly, when compared with normal samples,
DRD2 expression was elevated signiﬁcantly in CP, which is
a known major risk factor for PDAC,11 suggesting that DRD2
overexpression may be involved in the early steps of PDAC
development. In line with this observation, Sachlos and
colleagues34 have shown that dopamine receptors are
overexpressed in human cancer stem cells and that inhibi-
tion of dopamine receptor signaling can serve as an effec-
tive approach to impair tumorigenicity of cancer stem cells.
Notably, both studies utilized DRD2 antagonists that are
approved by the FDA as antipsychotic agents (pimozide and
haloperidol in our study and thriodazine in Sachlos
et al). Interestingly, schizophrenic patients receiving DRD224 October 2016  1:19 pm  ce
1320
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PANCREASantagonists have a reduced incidence rate of different solid
tumors, including those of rectum, colon, and prostate,
compared with the general population.35 Likewise, lower
cancer incidence rates have been reported in patients
suffering from Parkinson’s disease in which the dopami-
nergic pathway is deﬁcient.36 These ﬁndings suggest that
dopaminergic signaling may be involved in the development
of multiple cancers, and may potentially serve as a pan-
cancer therapeutic target. Supporting this, DRD2 antago-
nists have also shown anti-cancer effects in leukemia34 and
glioblastoma.29 However, other effectors including signal
transducer and activator of transcription 5 and extracellular
signalregulated kinase signaling have been proposed as
mediators of DRD2 function in these tumors. Notably, we
did not observe a decrease in phosphorylation of signal
transducer and activator of transcription 5 or extracellular
signalregulated kinase in PDAC cells upon treatment with
DRD2 antagonists (Supplementary Figure 5), but validated
that the anti-growth effect of pimozide and haloperidol on
pancreatic cancer cells is primarily through targeting
DRD2 (Supplementary Figure 6). Given the inherent
heterogeneous nature of cancer and the involvement of
GPCRs in multiple signaling cascades,8 it is possible that
the functional consequences of DRD2 blockade are
mediated through various signaling pathways in different
tumors. Additional experiments are warranted to elucidate
the exact mechanism of DRD2 inhibition in pancreatic
cancer.
Our study highlights the potential of DRD2 antagonism
as a possible therapeutic approach in pancreatic cancer,
which could be facilitated through a drug-repositioning
strategy, as previously practiced for pimozide in treatment
of metastatic melanoma.37 This also motivates future
studies to investigate possible relationships between
DRD2 levels and different PDAC subtypes, emerged by
transciptome38 and metabolite proﬁling,39 which may
lead to a better understanding of DRD2 function in








Note: To access the supplementary material accompanying
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